Is There Already a Need of Reckoning on Cancer Immunotherapy?
Main Authors: | Pierpaolo Correale, Francesca Pentimalli, Giovanni Baglio, Marjia Krstic-Demonacos, Rita Emilena Saladino, Antonio Giordano, Luciano Mutti |
---|---|
Format: | Article |
Jezik: | English |
Izdano: |
Frontiers Media S.A.
2021-03-01
|
Serija: | Frontiers in Pharmacology |
Teme: | |
Online dostop: | https://www.frontiersin.org/articles/10.3389/fphar.2021.638279/full |
Podobne knjige/članki
-
Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?
od: Luciano Mutti, et al.
Izdano: (2020-05-01) -
Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
od: Roger Y. Kim, MD, et al.
Izdano: (2021-06-01) -
Intratumor microbiota as a novel potential prognostic indicator in mesothelioma
od: Francesca Pentimalli, et al.
Izdano: (2023-03-01) -
Current status and progress in immunotherapy for malignant pleural mesothelioma
od: Boyang Sun, et al.
Izdano: (2022-06-01) -
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
od: Valerio Nardone, et al.
Izdano: (2021-11-01)